BioNexus Gene Lab (BGLC) Stock Overview
Through its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
BGLC Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
America Wants Homegrown Drones — Draganfly Is Ready to Deliver
Key Takeaways Draganfly is one of the most experienced drone manufacturers worldwide, boasting nearly three decades of innovation, and is now emerging as a North American leader in secure, NDAA-compliant drones. The company is riding massive industry tailwinds as Western governments shift away from Chinese-made drones, funneling billions into trusted domestic suppliers.Read more
BioNexus Gene Lab Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.14 |
| 52 Week High | US$15.60 |
| 52 Week Low | US$2.01 |
| Beta | 2.21 |
| 1 Month Change | -8.81% |
| 3 Month Change | -26.73% |
| 1 Year Change | 54.88% |
| 3 Year Change | -96.37% |
| 5 Year Change | -98.50% |
| Change since IPO | -91.59% |
Recent News & Updates
Shareholder Returns
| BGLC | US Trade Distributors | US Market | |
|---|---|---|---|
| 7D | -2.1% | -0.2% | 1.2% |
| 1Y | 54.9% | 11.5% | 15.8% |
Return vs Industry: BGLC exceeded the US Trade Distributors industry which returned 11.8% over the past year.
Return vs Market: BGLC exceeded the US Market which returned 15.8% over the past year.
Price Volatility
| BGLC volatility | |
|---|---|
| BGLC Average Weekly Movement | 6.5% |
| Trade Distributors Industry Average Movement | 5.8% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: BGLC has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BGLC's weekly volatility has decreased from 43% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 30 | Lee Tan | www.bionexusgenelab.com |
BioNexus Gene Lab Corp., through its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; and Investment Holding. It offers various chemical raw material products, including polyester resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; polyester resin 9509, a general-purpose material used in the production of marine boats and water slides; and polyester resin 2802, which is used as a component in the pultrusion process.
BioNexus Gene Lab Corp. Fundamentals Summary
| BGLC fundamental statistics | |
|---|---|
| Market cap | US$9.81m |
| Earnings (TTM) | -US$2.30m |
| Revenue (TTM) | US$9.47m |
Is BGLC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BGLC income statement (TTM) | |
|---|---|
| Revenue | US$9.47m |
| Cost of Revenue | US$8.07m |
| Gross Profit | US$1.40m |
| Other Expenses | US$3.70m |
| Earnings | -US$2.30m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.97 |
| Gross Margin | 14.77% |
| Net Profit Margin | -24.27% |
| Debt/Equity Ratio | 0.7% |
How did BGLC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/26 09:44 |
| End of Day Share Price | 2025/12/26 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioNexus Gene Lab Corp. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.